{"url_path":"/sec/nxl/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-08","source_url":"https://www.sec.gov/Archives/edgar/data/1527352/0001829126-26-004854-index.html","accession_number":"0001829126-26-004854","cik":"0001527352","ticker":"NXL","issuer_name":"Nexalin Technology, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1527352/0001829126-26-004854-index.html","primary_entity_key":"0001527352","primary_entity_name":"Nexalin Technology, Inc."},"word_count":387,"has_tables":true,"body_markdown":"**Item 6. Exhibits**\n\n \n\n**Exhibits and Financial Statement Schedules.**\n\n \n\n(a)\nExhibits.\n\n \n\n**Exhibit Number**\n** **\n**Description of Document**\n\n3.1(1)\n \n[Certificate of Incorporation, as amended and as currently in effect.](https://www.sec.gov/Archives/edgar/data/1527352/000182912622007966/nexalintechnology_ex3-1.htm)\n\n3.2(1)\n \n[Amended and Restated Bylaws](https://www.sec.gov/Archives/edgar/data/1527352/000182912622016146/nexalin_ex3-2.htm)\n\n4.1(1)\n \n[Form of Specimen stock certificate evidencing shares of common stock](https://www.sec.gov/Archives/edgar/data/1527352/000089109222000235/e14909ex4-1.htm)\n\n10.1(2)(4)\n \n[Scope of Work between the Company and Lindus Health Limited entered into on April 17, 2026.](nexalintechno_ex10-1.htm)\n\n31.1(2)\n \n[Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended](nexalintechno_ex31-1.htm)\n\n31.2(2)\n \n[Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended](nexalintechno_ex31-2.htm)\n\n32.1(3)\n \n[Certification of the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](nexalintechno_ex32-1.htm)\n\n32.2(3)\n \n[Certification of the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](nexalintechno_ex32-2.htm)\n\n101.INS(2)\n \nInline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)\n\n101.SCH(2)\n \nInline XBRL Taxonomy Extension Schema Document\n\n101.CAL(2)\n \nInline XBRL Taxonomy Extension Calculation Linkbase Document\n\n101.DEF(2)\n \nInline XBRL Taxonomy Extension Definition Linkbase Document\n\n101.LAB(2)\n \nInline XBRL Taxonomy Extension Label Linkbase Document\n\n101.PRE(2)\n \nInline XBRL Taxonomy Extension Presentation Linkbase Document\n\n104\n \nCover Page Interactive Data File (formatted in Inline XBRL, and included in exhibit 101).\n\n \n\n \n\n(1)\nPreviously filed as an exhibit to Form S-1 as declared effective by the SEC on September 15, 2022 (SEC File Number 333-261989).\n\n(2)\nFiled as an exhibit to this Form 10-Q.\n\n(3)\nFurnished herewith.\n\n(4)\nPursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit were omitted by means of marking such portions\nwith an asterisk because the identified confidential portions (i) are not material and (ii) are the type that the Company treats as private\nor confidential. The Company hereby agrees to furnish a copy of any redacted portion to the SEC upon request.\n\n \n\n27\n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n \n**Nexalin Technology, Inc.**\n\n \n \n \n\n \nBy:\n/s/ Mark White\n\nDated: May 8, 2026\n \nMark White\n\n \n \n\nChief Executive Officer\nPrincipal Executive Officer\n\n \n\n28"}